Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on January 29, 2020. The report details a material amendment to an existing Equity Distribution Agreement with A.G.P./Alliance Global Partners.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or margins. The only financial figures disclosed relate to the capital raising agreement:
- Original Offering Cap: $6,000,000
- Amended Offering Cap: $551,576
- Amount Raised to Date: $351,576
- Remaining Capacity: $200,000 (inclusive of the $351,576 raised)
Material Changes
The primary material change is the reduction of the maximum aggregate offering price under the Equity Distribution Agreement. The Company amended the agreement to lower the total amount to be raised from $6,000,000 to $551,576. This adjustment reflects the $351,576 already raised under the agreement, leaving a remaining capacity of approximately $200,000.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard disclosure that the report does not constitute an offer to sell securities. The Company directs investors to the effective Registration Statement on Form S-3 (File No. 333-220632) and associated prospectuses for detailed information regarding the securities offering.
Investor Verification Checklist
- Verify the current status of the $351,576 raised to date and the remaining $200,000 capacity under the amended agreement.
- Review the effective Registration Statement on Form S-3 (File No. 333-220632) and the prospectus supplement dated October 30, 2019, for terms of the offering.
- Confirm the Company's cash position and burn rate in the most recent 10-K or 10-Q filings, as this 8-K does not provide liquidity data.
- Monitor future filings for any further amendments to the Equity Distribution Agreement or new financing activities.